Telmisartan
Telmisartan (INN) /tɛlmɪˈsɑːrtən/ is an angiotensin II receptor antagonist (angiotensin receptor blocker, ARB) used in the management of hypertension. It was discovered by Boehringer Ingelheim and launched in 1999 as Micardis
Starting at
Product Description
| 2-(4-{[4-Methyl-6-(1-methyl-1H-1,3-benzodiazol-2-yl)-2-propyl-1H-1,3-benzodiazol-1-yl]methyl}phenyl)benzoic acid |
| Trade names | Micardis |
|---|---|
| AHFS/Drugs.com | monograph |
| MedlinePlus | a601249 |
| Pregnancy category |
|
| Legal status |
|
| Routes of administration | Oral |
| Bioavailability | 42–100% |
|---|---|
| Protein binding | ≥99.5% |
| Metabolism | Minimal hepatic |
| Biological half-life | 24 hours |
| Excretion | Faecal 97% |
| CAS Number | 144701-48-4 |
|---|---|
| ATC code | C09CA07 |
| PubChem | CID: 65999 |
| IUPHAR/BPS | 592 |
| DrugBank | DB00966 |
| ChemSpider | 59391 |
| UNII | U5SYW473RQ |
| KEGG | D00627 |
| ChEBI | CHEBI:9434 |
| ChEMBL | CHEMBL1017 |
| Formula | C33H30N4O2 |
|---|---|
| Molecular mass | 514.617 g/mol |
|
SMILES[show] |
|
|
InChI[show] |
|
